Signifor® LAR (pasireotide) Injectable Suspension

Signifor LAR is covered for FDA‑approved indications (acromegaly after inadequate surgery or when surgery isn't an option; Cushing's disease when pituitary surgery is not an option or not curative) and for specific compendial off‑label Cushing's uses (awaiting surgery or awaiting radiotherapy response); other uses are excluded. Approval requires indication‑specific documentation (e.g., baseline IGF‑1 > ULN for acromegaly; evidence of response or documented surgical ineligibility for Cushing's), prescription by or consultation with an endocrinologist/Cushing specialist, adherence to specified dosing and escalation limits, required labs/prior‑treatment records, and time‑limited approvals (4 months for awaiting uses, 12 months otherwise).

"Acromegaly in individuals who have had an inadequate response to surgery and/or for whom surgery is not an option (FDA‑approved indication)."